At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of the prostate
- ✕Prior prostate cancer treatment including chemotherapy and/or pelvic radiation
- ✕Active inflammatory bowel disease (diverticulitis, Crohn's disease, or ulcerative colitis) affecting the rectum
- ✕History of hip replacement
- ✕Prior intrapelvic surgery including transrectal/rectal surgery (except polypectomy, hemorrhoid removal/banding), transabdominal pelvic surgery, or bladder surgery
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma
In Brief
A clinical study evaluating < 15% risk of + LN and > 15% risk of + LN for Prostate Cancer. Completed, enrolled 77 participants across 1 site.
Detailed Summary
The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.
Study Details
Timeline
Interventions
Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.